

Slovenia

low HIV prevalence, around 5% prevalence among MSM.
Concentrated epidemic, 70-80% of all new cases are MSM.

PrEP advocacy started in 2014.

PrEP trial planned already in 2017, expected to start in March 2018.

Barriers: high cost, can't be covered by insurance because is for prevention purposes,

Research will be financed by Research agency and MH,

Duration 19 months, Initially for 50 participants.

Opportunities: generics are coming, prices are decreasing, we have KRKA, PLIVA, TEVA in the region!

PrEP made in pharmacy apparently not legal, but could be purchased in Austrian pharmacy for 59 €.

